Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 5 minute read Pharma Industry News Lumosa Therapeutics reports Phase 2 functional gains for LT3001 in disabling acute ischemic stroke Lumosa Therapeutics’ LT3001 Phase 2 stroke data show functional gains beyond standard windows. Find out what this means for Phase 3 and investors. bySrinathFebruary 8, 2026